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Background/aim: Infective endocarditis (IE) is still a significant cause of morbidity and mortality among cardiovascular diseases.
ENDOCARDITIS-TR study aims to evaluate the compliance of the diagnostic and therapeutic methods being used in Turkey with
current guidelines.
Materials and methods: The ENDOCARDITIS-TR trial is a multicentre, prospective, observational study consisting of patients admitted
to tertiary centres with a definite diagnose of IE. In addition to the demographic, clinical, microbiological, and echocardiographic
findings of the patients, adverse events, indications for surgery, and in-hospital mortality were recorded during a 2-year time interval.
Results: A total of 208 IE patients from 7 tertiary centres in Turkey were enrolled in the study. The study population included 125
(60.1%) native valve IE (NVE), 65 (31.3%) prosthetic IE (PVIE), and 18 (8.7%) intracardiac device-related IE (CDRIE). One hundred
thirty-five patients (64.9%) were culture positive, and the most frequent pathogenic agent was methicillin-susceptible Staphylococcus
aureus (MSSA) (18.3%). Among 155 (74.5%) patients with an indication for surgery, only 87 (56.1%) patients underwent surgery. The
all-cause mortality rate was 29.3% in-hospital follow-up. Multivariable Cox regression analysis revealed that absence of surgery when
indicated (HR: 3.29 95% CI: 0.93–11.64 p = 0.05), albumin level at admission (HR: 0.46 95% CI: 0.29–0.73 P < 0.01), abscess formation
(HR: 2.11 95% CI: 1.01–4.38 p = 0.04) and systemic embolism (HR: 1.78 95% CI: 1.05–3.02 p = 0.03) were ascertained independent
predictors of in-hospital all-cause mortality.
Conclusion: The short-term results of the ENDOCARDITIS-TR trial showed the high frequency of staphylococcal IE, relatively high
in-hospital mortality rates, shortage of surgical treatment despite guideline-based surgical indications and low usage of novel imaging
techniques. The results of this study will provide a better insight to physicians in respect to their adherence to clinical practice guidelines.
Key words: Infective endocarditis, in-hospital mortality, heart valve disease

1. Introduction
Despite advances in diagnostic and therapeutic approaches,
infective endocarditis (IE) remains a significant cause of
morbidity and mortality among cardiovascular diseases
[1]. The disease’s poor outcome necessitates not only to
recognize the clinical picture and initiate appropriate
antibiotic therapy immediately but also to define the
prognostic predictors better.
For that purpose, novel strategies such as additional
noninvasive imaging modalities, including multislice
computed tomography (MSCT), magnetic resonance

imaging, nuclear imaging, and therapeutic strategies
consisting of early surgery of complicated cases, have been
recommended by the European Society of Cardiology
(ESC) guidelines [2]. Nonetheless, it is uncertain whether
these recommendations are being implemented in our
daily practice in Turkey.
ENDOCARDITIS-TR study aims to evaluate the
compliance of the diagnostic and therapeutic methods
being used in Turkey with current guidelines. Also,
epidemiological, clinical, microbiological, and prognostic
features of the IE patients have been assessed.

* Correspondence: calik_nazmi@hotmail.com

This work is licensed under a Creative Commons Attribution 4.0 International License.
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2. Materials and methods
2.1. Study design and population
The ENDOCARDITIS-TR trial is a multi-centre,
prospective, observational study consisting of patients
referred to or admitted to tertiary centres and diagnosed
with definite IE following ESC 2015 IE diagnostic criteria.
Between 1 February 2018 and 1 February 2020, predefined
centres recruited patients presenting with IE and older
than 18 years old in the study. Informed consent was
obtained from all participants.
2.2. Data collection and clinical follow-up
In addition to the patients’ demographic, clinical and
microbiological findings, adverse events, indications for
surgery, and in-hospital mortality were recorded during a
2-year time interval.
2.3. Echocardiography and other imaging tools
The data regarding imaging techniques such as
transthoracic and transesophageal echocardiography,
multislice computed tomography (MSCT), and nuclear
imaging findings were noted.
2.4. Definitions and microbiological parameters
Following the 2015 ESC guidelines for the management of
infective endocarditis, only the patients having ‘definitive
IE diagnosis’ were included in our study. For this reason,
at least three sets were taken at 30-min intervals, each
containing 10 mL of blood, and were incubated in both
aerobic and anaerobic atmospheres. Blood sampling was
obtained from a peripheral vein instead of a central venous
catheter (because of the risk of contamination) using a
meticulous sterile technique.
Transient ischemic attacks (TIAs) have been defined
as brief episodes of neurologic dysfunction resulting from
focal cerebral ischemia not associated with permanent
cerebral infarction, while ischemic stroke was defined as
an episode of neurological dysfunction caused by focal
cerebral, spinal, or retinal infarction [3,4].
2.5. Statistical analysis
All data were presented as a mean ± SD for variables with
normal distribution or a median [inter-quantile range]
for variables with nonnormal distribution. Categorical
variables were reported as numbers and percentages.
Continuous variables were checked for the normal
distribution assumption using Kolmogorov-Smirnov
statistics. Categorical variables were tested by Pearson’s
χ2 test and Fisher’s Exact Test. Differences between
groups were evaluated using the Mann–Whitney U test
or the Student t-test, when appropriate. The comparison
of three groups, where indicated, was performed by
using one-way ANOVA or Kruskal Wallis tests following
their distribution. A further Tukey posthoc analysis
was performed for the variables that were considered
statistically significant. Univariable and multivariable
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Cox regression analyses were performed to investigate
the independent correlates of all-cause mortality. As
a result of the univariable Cox regression analyses,
variables that have P values < 0.10 were included in the
multivariable Cox regression analyses. P-values were
two-sided, and values <0.05 were considered statistically
significant. Since the main objective of our study was to
evaluate the association between in-hospital mortality
and the situation of not receiving surgical intervention
even there is a guideline-based indication, the power of
the study was assessed using this parameter. The power
of the study and the minimum number of patients to be
included were calculated following the interim analysis
results consisting of the assessment of the first 50 patients
enrolled. Considering the type 1 error rate of 0.05 and to
achieve 80% power, we calculated that a minimum of 98
patients would be required to claim significant results. All
statistical studies were carried out using Statistical Package
for Social Sciences software (SPSS 22.0 for Windows, SPSS
Inc., Chicago, Illinois)
The study was approved by the local ethics committee
(HNEAH-KAEK 2017/KK/152), and it was performed
according to the principles of the Declaration of Helsinki.
3. Results
A total of 208 infective endocarditis (IE) patients from
7 tertiary centres located in different Turkey regions
were enrolled in the study. Demographic and clinical
characteristics of patients were summarized in Table 1.
The study population included 125 (60.1%) native valve
IE (NVE), 65 (31.3%) prosthetic IE (PVIE), and 18 (8.7%)
intracardiac device-related IE (CDRIE). The mean age
was 58.3 ± 14.8 years and was similar between the three
groups. Eighty-three patients (39.9%) were female, and
the frequency of the female gender was high in the PVIE
group (p = 0.01). While the frequency of coronary artery
disease (CAD) and heart failure (HF) was higher in the
CDRIE group, atrial fibrillation (AF) was higher in the
PVIE group. The groups were comparable in terms of
other demographic features, clinical presentation, and
symptoms (Table 2). The most frequent symptom on
admission was fever in the study population (72.6%).
One hundred thirty-five patients (64.9%) were culture
positive, and the most frequent pathogenic agent was
methicillin-susceptible Staphylococcus aureus (MSSA)
in the overall study group (18.3%). While the frequency
of the MSSA and methicillin-resistant Staphylococcus
aureus (MRSA) were numerically higher in the CDRIE
group, streptococcus viridans were numerically higher in
the NVE group. Candida IE was observed only in the NVE
group (6 patients) (Table 3). TEE was performed in 189
patients (91%). Fluorodeoxyglucose-positron emission
tomography (FDG PET/CT) usage as an imaging modality
was relatively low in our study population (5%). (Table 4)
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Table 1. Patient demographics and clinical characteristics.
Total

Native

Prosthetic

CDRIE

P

Total, N (%)

208

125 (60.1)

65 (31.3)

18 (8.7)

Mean age ± SD

58.3 ± 14.8

57.8 ± 14.9

59.3 ± 13.9

58.7 ± 17.1

0.81

Females, N (%)

83 (39.9)

46 (36.8)

34 (52.3)

3 (16.7)

0.01

Coronary artery disease

81 (38.9)

41 (32.8)

29 (44.6)

11 (61.1)

0.04

Heart failure

48 (23.1)

19 (15.2)

16 (24.6)

13 (72.2)

<0.01

Atrial fibrillation

50 (24.0)

16 (12.8)

31 (47.7)

4 (22.2)

<0.01

Congenital heart disease

15 (7.2)

11 (8.8)

3 (4.6)

1 (5.6)

0.54

Previous endocarditis

17 (8.2)

7 (5.6)

9 (13.8)

1 (5.6)

0.13

Pacemaker

9 (4.3)

-

4 (6.2)

5 (27.8)

<0.01

ICD

6 (2.9)

1 (0.8)

-

5 (27.8)

<0.01

CRT-D

7 (3.4)

-

-

7 (38.9)

-

Hypertension

94 (45.2)

56 (44.8)

30 (46.2)

8 (44.4)

0.98

Chronic renal failure
Hemodialysis

65 (31.3)
30 (14.4)

42 (33.6)
23 (18.3)

17 (26.2)
7 (10.8)

6 (33.3)
-

0.56
0.07

Asthma/COPD

16 (7.7)

8 (6.4)

5 (7.7)

3 (16.7)

0.31

Previous stroke/TIA

42 (20.2)

26 (20.7)

14 (21.5)

3 (16.7

0.89

Malignancy

31 (14.9)

20 (16)

10 (15.4)

1 (5.6)

0.50

Immunosuppressive treatment

19 (9.1)

15 (12)

3 (4.6)

1 (5.6)

0.21

Chronic autoimmune disease

22 (10.6)

14 (11.2)

7 (10.8)

1 (5.6)

0.76

Intravenous drug abuse

21 (10.1)

16 (12.8)

3 (4.6)

2 (11.1)

0.20

Alcohol abuse

21 (10.1)

13 (10.4)

7 (10.8)

1 (5.6)

0.79

Smoking

96 (46.2)

64 (51.2)

25 (38.5)

8 (44.4)

0.29

History of CV diseases, n (%)

Risk Factors, n (%)

CDRIE, Cardiac device-related infective endocarditis; ICD, Intracardiac defibrilator;
CRT-D, Cardiac resynchronization therapy with ICD; COPD, Chronic obstructive pulmonary disease;
TIA, Transient ischaemic attack.

Table 2. Clinical presentation.
Total
(N = 208)

Native
(N = 125)

Prosthetic
(N = 65)

CDRIE
(N = 18)

P

Fever

151 (72.6)

85 (68)

52 (80)

14 (77.8)

0.18

Constitutional symptoms

143 (68.8)

85 (68)

47 (72.3)

12 (66.7)

0.75

Dyspnea

132 (63.6)

87 (69.6)

36 (55.4)

10 (55.6)

0.14

Chest pain

43 (20.7)

29 (23.2)

10 (15.4)

5 (27.8)

0.38

Stroke-TIA

33 (15.9)

21 (16.8)

10 (15.4)

3 (16.7)

0.98

Syncope

12 (5.8)

7 (5.6)

4 (6.2)

1 (5.6)

0.98

NYHA III-IV

81 (38.9)

48 (38.4)

24 (36.9)

9 (50)

0.62

CDRIE, Cardiac device-related infective endocarditis; TIA, Transient ischaemic attack;
NYHA, New York Heart Association.
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Table 3. Laboratory parameters and blood cultures.
Total
(N = 208)

Native
(N = 125)

Prosthetic
(N = 65)

CDRIE
(N = 18)

P

C-reactive Protein, mg/dL

8.9 [11]

7.5 [8.6]

7.7 [11.8]

7.8 [14.1]

0.78

Procalsitonin, ng/mL

0.45 [6.4]

0.8 [6.3]

0.3 [21.8]

0.1 [2.6]

0.94

hs-Troponin I, ng/mL

0.03 [0.43]

0.1 [0.5]

0.1 [0.1]

0.04 [1.1]

0.21

Pro-BNP, pg/mL

417 [1074]

459 [1207]

220 [740.2]

640 [541.5]

0.65

WBC, 10 /uL

10.9 ± 5.3

11.1 ± 5.3

10.9 ± 5.5

9.6 ± 4.8

0.57

Platelet, 10 /uL

235.2 ± 99.2

219.2 ± 77

245.3 ± 95.6

232.4 ± 103.9 0.54

Hemoglobin, g/dL

10.5 ± 2.1

10.4 ± 2.0

10.5 ± 2.1

10.8 ± 2.5

0.75

Blood culture (-) patients, n (%)

73 (35.1)

21 (33.8)

25 (38.5)

7 (38.9)

0.54

Blood culture (+) patients, n (%)

Laboratory parameters

3

3

Blood Cultures
135 (64.9)

84 (67.2)

40 (61.5)

11 (61.1)

0.69

MSSA

38 (18.3)

20 (16.0)

14 (21.5)

5 (27.8)

0.31

MRSA

14 (6.7)

9 (7.2)

2 (3.1)

3 (16.7)

0.11

Coagulase (-) stafilococcus

28 (13.5)

18 (14.4)

7 (10.8)

3 (16.7)

0.72

Enterococcus spp.

24 (11.5)

19 (15.2)

6 (9.2)

-

0.15

Streptococcus Viridans

19 (9.1)

14 (11.2)

4 (6.2)

1 (5.6)

0.44

Candida

6 (2.9)

6 (4.8)

-

-

-

Gram-negative bacillus

6 (2.9)

2 (1.6)

4 (6.2)

-

0.39

CDRIE, cardiac device-related infective endocarditis; BNP, Brain natriuretic peptide;
WBC, White blood cells; MSSA, Methicillin-susceptible Staphylococcus aureus;
MRSA, Methicillin-resistant Staphylococcus aureus.
Table 4. Imaging methods and findings.
Total
(N = 208)

Native
(N = 125)

Prosthetic
(N = 65)

CDRIE
(N = 18)

P

TTE

208 (100)

125 (100)

65 (100)

18 (100)

-

TOE

189 (90.8)

112 (89.6)

62 (95.4)

15 (83.3)

0.17

FDG PET/CT Scan

10 (4.8)

4 (3.2)

6 (9.2)

-

0.11

≥10 mm vegetation

95 (45.3)

66 (52.8)

23 (35.4)

6 (33.3)

0.04

Abscess

22 (10.6)

16 (12.8)

6 (9.2)

-

0.23

Pseudoaneurysm

9 (4.3)

2 (1.6)

7 (10.8)

Paravalvular leakage

23 (11.1)

-

23 (35.4)

-

<0.01

Prosthetic dehiscence

5 (2.4)

-

5 (7.7)

-

<0.01

Methods, n (%)

Findings, n (%)

<0.01

CDRIE, Cardiac device-related infective endocarditis;
TTE, TransThoracic echocardiography; TOE, TransOesophageal echocardiography

Among 155 (74.5%) patients with an indication for
surgery according to the ESC guidelines, only 87 (56.1%)
patients underwent surgery. Surgery was not performed
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in 68 (43.9%) patients despite an indication. Particularly
in the PVIE group, cardiac surgery was only performed
in 12 out of 40 (30%) patients who indicated surgical
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treatment. Regarding the CDRIE group, lead extraction,
either percutaneously or surgically, was successfully
performed in 13 out of 14 patients. The most common
indication for cardiac surgery was HF (57.2%), and it was
significantly higher in the NVE group compared to other
types of IE (p < 0.01). (Table 5)
The all-cause mortality rate was 29.3% in-hospital
follow-up. The mean in-hospital follow-up time was 37
days, including four day-stay in the intensive care unit
(ICU), with no differences between the groups. (Table 6)
We performed univariable and multivariable
binary regression analysis for all variables to identify
the independent predictors of all-cause mortality. In
univariable regression analyses, age, abscess formation,
albumin level at admission, heart failure, uncontrolled
infection, systemic embolism, and presence or absence

of cardiac surgery when indicated were found to be
correlated with all-cause mortality. (Table 7)
After applying these variables into the multivariable
Cox regression analysis, absence of surgery when
indicated (HR: 3.29 95% CI: 0.93–11.64 p = 0.05),
albumin level at admission (HR: 0.46 95% CI: 0.29–0.73
p < 0.01), abscess formation (HR: 2.11 95% CI: 1.01–4.38
p = 0.04) and systemic embolism (HR: 1.78 95% CI:
1.05–3.02 p = 0.03) were ascertained as independent
predictors of in-hospital all-cause mortality (Table 7).
Table 8 indicates the comparison of demographic
and clinical features between in-hospital death and
survival group. Besides being older than the survivors,
the albumin levels were found to be significantly lower
in the mortality group. IE complications requiring
surgery such as heart failure, uncontrolled infection,

Table 5. Indications and timing of cardiac surgery.
Total
(N = 208)

Native
(N = 125)

Prosthetic
(N = 65)

CDRIE
(N = 18)

P

155 (74.5)

101 (80.8)

40 (61.5)

14 (77.7)

0.02

Heart failure

119 (57.2)

85 (68)

29 (44.6)

5 (27.8)

<0.01

Uncontrolled infection

91 (43.8)

49 (39.2)

30 (46.2)

12 (66.7)

0.08

Systemic embolism

57 (27.4)

37 (29.3)

18 (27.7)

4 (22.2)

0.87

87 (56.1)

62 (61.3)

12 (30)

13 (92.8) *

<0.01

40
47

31
31

1
11

8
5

68 (43.9)

39 (38.3)

28 (70)

1 (7.2) *

Surgical indication, n (%)

Cardiac surgery performed
<2 week
>2 week
Cardiac surgery not performed

<0.01

CDRIE, Cardiac device-related infective endocarditis
* 13 out of 14 CDRIE patients underwent successful device removal.
Table 6. In-hospital follow-up and causes of mortality.
Total
(N = 208)

Native
(N = 125)

Prosthetic
(N = 65)

CDRIE
(N = 18)

P

In-hospital follow-up, days
ICU follow-up, days

37.2 ± 25.6
4 [10]

37.5 ± 27.8
4 [9]

36.6 ± 23.3
3.5 [8]

35.5 ± 18.1
4.5 [10.2]

0.49
0.24

In-hospital mortality, n (%)

61 (29.3)

38 (30.4)

19 (29.2)

4 (22.2)

0.77

Heart failure

49 (23.5)

34 (27.2)

11 (16.9)

4 (22.2)

0.28

Arrhythmias

23 (11.1)

8 (6.4)

11 (16.9)

4 (22.2)

0.02

Cerebral embolism

32 (15.4)

16 (12.8)

14 (21.5)

2 (11.1)

0.24

Peripheral embolism

13 (6.3)

7 (5.6)

6 (9.2)

-

0.32

Acute myocardial infarction

10 (4.8)

7 (5.6)

2 (3.1)

1 (5.6)

0.73

Sepsis

53 (25.5)

30 (24)

19 (29.2)

4 (22.2)

0.69

Malignancy

6 (2.9)

6 (4.8)

-

-

-

CDRIE, Cardiac device-related infective endocarditis; ICU, Intensive care unit.
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Table 7. Univariate and multivariate regression analysis for predictors of in-hospital mortality.
Univariate
analysis

Multivariate
analysis

HR

CI

P

HR

CI

P

Heart failure

4.49

[2.21–9.13]

<0.01

1.01

[0.52–1.94]

0.97

Uncontrolled infection

3.23

[1.73–6.03]

<0.01

1.53

[0.83–2.80]

0.16

Systemic embolism

0.25

[0.13–0.51]

<0.01

1.78

[1.05–3.02]

0.03

Albumin (at admission)

1.03

[1.01–1.06]

<0.01

0.46

[0.29–0.73]

<0.01

Age

2.72

[1.11–6.66]

0.03

1.00

[0.98–1.02]

0.49

Abscess

3.45

[1.81–6.59]

<0.01

2.11

[1.01–4.38]

0.04

Indication for surgery – performed

4.78

[1.09–14.87]

<0.01

0.91

[0.26–3.18]

0.89

Indication for surgery – not performed

3.9

[1.2–12]

<0.01

3.29

[0.93–11.64]

0.05

P <0.05 was considered as a statistically significant difference,
HR, Hazard ratio; CI, Confidence interval.

systemic embolism and abscess were more frequent in
the mortality group.
In Kaplan-Meier curves, patients who did not undergo
surgery despite an indication had a significantly higher risk
for total mortality compared to other patients having no
indication for surgery or undergoing surgery when there
is an indication (Log-Rank p < 0.01) (Figure 1). According
to the survival table, Kaplan-Meier estimates of 60-days
cumulative survival rates between groups (no indication of
surgery, indication/surgery performed, indication/surgery
not performed) were 87%, 65%, and 21%, respectively.
Also, according to the Kaplan-Meier survival analysis,
total mortality risk did not differ between groups in terms
of endocarditis type (Log-Rank p = 0.84) (Figure 2).
4. Discussion
Our study’s most remarkable findings are: (i) The inhospital mortality rate was extremely high, with 29.3%
(ii) Surgery was not performed in 43.9% of the patients
despite an indication. Even in the PVIE group, cardiac
surgery was performed only in 30 % of the patients who
indicated surgical treatment. (iii) FDG PET/CT was used
for only 5% of the patients in our study population. (iv)
The absence of surgery when indicated, albumin level at
admission, abscess formation, and systemic embolism
were the independent predictors of in-hospital all-cause
mortality. Although there were some previous reports from
our country about IE [5-7], this study aimed to investigate
the changing patterns of IE’s management, epidemiology,
and outcomes.
First, our cohort’s mean age was 58.3 years, with
comparable ages reported in the EURO-ENDO registry
in 2019 [8] and considerably higher than a previous study
(47 years) from Turkey, which was published in 2014 [9].

450

The previous studies have shown that the mean age of IE
patients in developing countries is lower than in highincome countries [10,11]. According to several previous
reports, we also know that the median ages of IE patients
are progressively increased over the years [8,12–14]. The
main underlying cause of the increasing median age
of IE patients according to the country’s development
level is the difference in risk factor profile. For instance,
rheumatic heart disease is a prominent risk factor for
infective endocarditis in young people living in developing
countries. In developed countries, people’s life expectancy
is high, so indwelling cardiac devices and intravenous
lines are widely used, which lead to health-care acquired
infective endocarditis as an increasing precursor in this
aged population. The mean age of patients with IE in our
study is the highest compared to other studies published
from Turkey to date. This finding can be explained by the
medical advances and the increased reach of health care
services by a broader population in the last years.
In our study, the proportion of the IE patients
according to the nidus (60.1% NVE, 31.3% PVIE, and
8.7% CDRIE) was also following the EURO-ENDO
registry. IE has been increasingly encountered in patients
with prosthetic valves and intra-cardiac devices over the
past two decades [1,15]. The most frequently identified
microorganism group was staphylococci in 38.5% of our
culture-positive IE patients. The most frequently observed
subspecies in the staphylococci group were MSSA, also
compatible with recent studies [1,8,9,15]. Staphylococci,
a major cause of healthcare-associated IE, has eclipsed
streptococci as the most common cause in many highincome countries. Streptococcal infective endocarditis
caused by the oral viridans group is the primary cause of
NVE and still the most identified pathogen in low-income
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Table 8. Comparison of demographic and clinical features between in-hospital death and survival group.
In-hospital death
(n = 61)

Survival group
(n = 147)

P

Age, year

63 ± 13.3

56.4 ± 15

<0.01

Male, n (%)

36 (59)

89 (60.5)

0.84

Ischemic heart disease, n (%)

32 (52.5)

74 (50.1)

0.10

History of heart failure, n (%)

17 (27.9)

31 (21.1)

0.29

Atrial fibrillation, n (%)

17 (27.9)

33 (22.4)

0.41

Congenital heart disease, n (%)

3 (4.9)

12 (8.2)

0.41

Previous episode of IE, n (%)

3 (4.9)

14 (9.5)

0.27

Pacemaker, n (%)

3 (4.9)

6 (4.1)

0.79

ICD, n (%)

3 (4.9)

3 (2)

0.26

CRT-D, n (%)

1 (1.6)

6 (4.1)

0.37

Hypertension, n (%)

31 (50.9)

63 (42.9)

0.29

Chronic kidney disease, n (%)

25 (41)

49 (33.3)

0.12

Dialysis, n (%)

12 (19.7)

18 (12.2)

0.16

Asthma/COPD, n (%)

5 (8.2)

11 (7.5)

0.86

Stroke-TIA, n (%)

12 (19.7)

30 (20.4)

0.90

Malignancy, n (%)

5 (8.2)

26 (17.7)

0.08

Connective tissue disorders, n (%)

6 (9.8)

16 (10.9)

0.82

Alcohol abuse, n (%)

7 (11.5)

14 (9.5)

0.67

Smoking, n (%)

26 (42.6)

70 (47.6)

0.51

Native valve IE

38 (62.3)

87 (59.2)

0.78

Prosthetic valve IE

19 (31.1)

46 (31.3)

0.56

Cardiac Device-Related IE

Endocarditis Type, n (%)

4 (6.6)

14 (9.5)

0.49

Surgical Indication, n (%)

59 (96.7)

96 (65.3)

< 0.01

Peak Troponin I Value, ng/µL

0.08 [0.9]

0.06 [0.15]

0.15

WBC, th/uL

12.3 ± 6.3

11.8 ± 4.8

0.22

Hemoglobin, g/L

10.4 ± 2.1

10.7 ± 2.1

0.09

Procalcitonin, ng/mL

1.5 [8.1]

1.2 [6.4]

0.06

Serum Creatinine, mg/dL

1.3 [1.6]

1.2 [1.1]

0.05

CRP, mg/dL

11.2 [7.4]

9.2 [11.2]

0.07

Neutrophil, 10³/µL

10 ± 4.6

9.8 ± 4.1

0.32

Albumin, g/dL

2.9 ± 0.5

3.3 ± 0.5

<0.01

BNP, pg/mL

552.5 [1360]

469 [825.7]

0.06

Heart failure

49 (80.3)

70 (47.6)

<0.01

Uncontrolled infection

39 (63.9)

52 (35.4)

<0.01

Systemic embolism

28 (45.9)

29 (19.7)

<0.01

Abscess

11 (18)

11 (7.5)

0.02

Complications of IE, n (%)

IE, Infective Endocarditis; ICD, Intracardiac defibrilator;
CRT-D, Cardiac resynchronization therapy with ICD; COPD, Chronic obstructive pulmonary disease;
TIA, Transient ischaemic attack; WBC, White blood cells;
CRP, C-reactive protein; BNP, Brain natriuretic peptide
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Figure 1. Cumulative survival in three subgroups according to the presence or absence of an
indication of surgery and whether surgery was performed or not.

Figure 2. The Kaplan-Meier curves for all-cause in-hospital mortality according to the type
of endocarditis.

countries [16]. Streptococci was the causative agent in only
9.1% of our IE patients. Our culture positivity rate was
64.9%, comparable to some of the previous studies [14,17],
but lower than the others [1,8,12,18–20]. About 10% of
patients with IE show no growth from blood cultures in
developed countries. A median of 68% (range 50–84%) of
IE causes has been identified in studies from Turkey [9].
The most common cause of culture-negative IE is prior
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antimicrobial therapy. Besides, the fastidious organisms
such as Brucella, Legionella, Chlamydia, Coxiella, and
fungi may be the underlying cause of culture-negative IE.
Several reports have shown that blood culture-negative IE
rates are much higher in developing countries [11,21–23].
Transthoracic echocardiography and TEE remain to
be the mainstay for the diagnosis of IE. There exist three
main areas of use for TEE in patients with IE. Firstly, for
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a definitive diagnosis to be made, TEE is the confirmatory
procedure performed even in patients with uncomplicated
native valve endocarditis diagnosed on TTE. Secondly,
complications of IE include perforations, abscesses, and
fistulae are evaluated with TEE. Thirdly, the follow-up of
blood culture-negative patients with high clinical suspicion
of native valve IE is also made with TEE. TTE and TEE are
widely available and were performed 100% and 91% of our
patients, respectively. 18F-FDG PET/CT is mainly used as
a novel diagnostic tool with a better sensitivity in PVIE
than in NVE and CDRIE, mainly when the diagnosis is
uncertain. 18F-FDG PET/CT was performed for 16.6% of
the patients in the EURO-ENDO registry. There is limited
access to 18F-FDG PET/CT in our country, which was
performed for only 5% of study patients.
The management of patients with IE requires an
“Endocarditis Team” approach for optimized patient care.
The Endocarditis Team generally includes cardiologists,
cardiothoracic surgeons, and infectious disease specialists.
The Endocarditis Team’s role was described in 2015 ESC
Guidelines [2] for the IE management comprehensively.
One of the most important Endocarditis Team tasks is the
selection of appropriate patients and timing for surgery.
The current reports indicate that early surgery significantly
reduces short and long-term mortality in patients with a
guideline-based surgical indication [24,25]. Surgery was
performed in more than one-half of the patients with IE
in previous reports [26]. The most frequent indications
for the surgery were valvular dysfunction leading to HF,
uncontrolled infection, and embolism prevention. The
most common indication for cardiac surgery was HF, and
it was significantly higher in the NVE group than other
types of IE in our study. Mortality was particularly high
in EURO-ENDO when surgery was indicated but not
performed. Similarly, the absence of surgery despite an
indication was found to be an independent predictor of
all-cause mortality in our study. There was an indication
for surgery in 74.5% of our patients, but nearly half of
those (43.9%) did not undergo surgery. Even though the
previous studies reported that nearly one-quarter of IE
patients with indications for surgery did not undergo
surgery during the initial hospitalization [27], the rate of
absence of surgery when indicated in our study (43.9%) is
relatively high compared to similar studies.
The most common reasons for the lack of surgery were
fragility, hemodynamic instability, stroke, sepsis, and death
before surgery in previous reports. In our study population,
the most frequent reasons for not undergoing surgery even
an indication were patient refusal due to high-risk surgery
and death or suffering from a neurological complication
while waiting for the operation.
The all-cause mortality rate was 29.3% in-hospital
follow-up of our IE patients. The in-hospital mortality

of IE was estimated at around 20% in previous studies
[28,29]. Simsek et al. have reported a very high mortality
rate (27.8%) in a recent single-centre study from Turkey
[9]. They have concluded that the higher mortality rate
could be due to the referral of more complicated cases to
their referral centre. Acknowledging this plausible reason
for our study conducted in Turkey’s referral centres, we
can further speculate that the main reason for our very
high mortality rate may be due to the very high rate of the
patients who did not undergo surgery despite an indication.
Therefore, it is not surprising to find the abscess formation
and systemic embolism as the independent predictors of
in-hospital mortality for our study. They are well-known
indications for surgery in patients with IE.
Last but not least, S. aureus has been found as the most
frequently identified microorganism in our study, which
was associated with a lower likelihood of surgery [29] and
high in-hospital mortality [8] in previous studies. This
may be another plausible reason for very high mortality
rates in our study population.
5. Conclusion
The short-term results of the multicentre, prospective,
and observational ENDOCARDITIS-TR trial showed
the high frequency of staphylococcal IE, relatively high
in-hospital mortality rates, shortage of surgical treatment
despite guideline-based surgical indications and low usage
of novel imaging techniques. The present study, despite
its limitations, sheds light on the clinical approach of IE
patients in Turkey’s referral centres by evaluating their
diagnostic and therapeutic features and clinical outcomes.
The results of this study will provide a better insight to
physicians in respect to their adherence to clinical practice
guidelines.
6. Limitations
The main limitations of our study may be listed as follows.
Firstly, the study consisted only of high-risk patients
admitted or referred to tertiary centres. This may have
prevented the study from reflecting population-based
outcomes and resulted in a higher rate of in-hospital
mortality than expected. Secondly, the data regarding the
reasons for the absence of surgical treatment should be
better provided. However, this does not change the fact
that such a conservative approach was an independent
predictor of in-hospital mortality. Thirdly, events occurring
during the long-term follow will be evaluated in the future
trials of ENDOCARDITIS-TR.
Informed consent
The study was approved by the local ethics committee
(HNEAH-KAEK 2017/KK/152), and it was performed
according to the principles of the Declaration of Helsinki.
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